NEI Podcast

In this episode, Dr. Andy Cutler sits down with Dr. Debbi Morrissette, Senior Director of Educational Development at NEI, to explore the magic behind NEI Congress. Tune in as they talk about the unique elements of NEI Congress that bring the visual language of psychopharmacology to life!  Are you ready to step up your clinical game? Join us at the 2025 NEI Fall Congress, Nov. 6–9 in Colorado Springs (or online via simulcast)! Explore a comprehensive program of psychopharmacology essentials: treatments, side effects, drug interactions, and more — all taught by top-tier faculty.  Special Offer for NEI Podcast Listeners: Register now and save $50 off your registration with code POD25FALL   Register today at https://nei.global/fall  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

Dr. Jeffrey Strawn, a leading expert in psychiatry from the University of Cincinnati, dives deep into the nuances of obsessive-compulsive disorder (OCD) with Dr. Andy Cutler. They discuss the importance of accurate diagnoses and the misdiagnosis of OCD due to stigma. The conversation explores evidence-based treatments including SSRIs and innovative therapies like ketamine. They emphasize neuroplasticity's role in therapy and advocate for a focus on functionality in mental health treatment. The need for personalized approaches in care also shines through.

In this CME podcast episode, Dr. Andrew Cutler interviews Dr. Phillip Coffin, Director of the Center on Substance Use and Health in San Francisco, CA, about the management of stimulant use disorders. They explore the challenges of treatment and highlight the importance of harm reduction strategies to enhance patients’ quality of life.  CME credit is available to NEI Members only.   Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Summarize pharmacologic and behavioral treatment strategies for stimulant use disorders, particularly methamphetamine and cocaine Evaluate the evidence base for current and investigational medications used in clinical trials and real-world settings Apply harm reduction principles and integrated care models to improve outcomes for patients with stimulant use disorders in diverse clinical settings Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: June 18, 2025*   Expiration: June 17, 2028 *NEI and HMP Education maintain a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-02.  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until June 17, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD, LFAPA specializing in psychiatry, forensic, addiction to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Phillip Coffin, MD, MIA Director of Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA No financial relationships to disclose. The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, Stephen Daniels and Bahgwan Bahroo, MD, LFAPA. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Today, Dr. Andy Cutler interviews Dr. Katharine Phillips about identifying and treating body dysmorphic disorder (BDD). Join the discussion as they talk about how BDD presents, the treatments available for this debilitating disorder, and how clinicians can help their patients reach remission.  Katharine Phillips, MD is a renowned psychiatrist and leading authority on body dysmorphic disorder (BDD). She serves as Professor of Psychiatry and DeWitt Wallace Senior Scholar at Weill Cornell Medical College and is an attending psychiatrist at New York-Presbyterian Hospital.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  BDD Treatment Manuals International OCD Foundation - BDD     Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

This episode includes extended Q&A sessions that address your unanswered questions from the following presentations delivered at the 2025 Spring Congress in Philadelphia, Pennsylvania:  (00:20) All the Tea on ADHD: Guidance for Developing Effective Treatment Strategies for Patients With ADHD by Andrew Cutler, MD   (20:20) You and I and an LAI: Benefits, Early Adoption, and Options for Patients With Serious Mental Illness Desiree Matthews, MSN, PMHNP-BC and Jonathan Meyer, MD (Q&A with Desiree Matthews)   (38:53) A Practical Guide to Ordering and Interpreting Kidney Function Tests by Rajnish Mago, MD   (59:13) Preventing the Progression From Casual to Casualty: An Update on Interventions for Substance Use Disorders by Hara Oyedeji, APRN, PMHNP-BC, MSN, MSEd and Andrew Cutler, MD (Q&A with Hara Oyedeji)    Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 

In this episode, Dr. Andy Cutler is joined by Dr. Jennifer Payne to discuss management of mood disorders influenced by fluctuations in reproductive hormones, particularly in women. They explore medication management during the perinatal period, emphasizing the risks associated with inadequately treated mood disorders. The conversation also addresses strategies for managing hormone-related mood disorders across reproductive stages, including premenstrual dysphoric disorder, premenstrual exacerbation, and perimenopausal depression. Jennifer L. Payne, MD is a psychiatrist specializing in reproductive psychiatry and mood disorders in women. She serves as Vice Chair of Research and Professor in the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, directing the Reproductive Psychiatry Research Program.  Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. 🌟Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25 Register today at nei.global/spcongress25a Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 

Join Dr. Andy Cutler and Dr. Cynthia Bulik as they discuss the challenges of diagnosing and treating binge eating disorder (BED). They explore the genetics, neurobiology, and clinical course of BED that inform treatment decisions, and examine how advances in genetic research and emerging pharmacological options may improve outcomes for individuals with BED.  Cynthia Bulik, PhD, FAED is a Distinguished Professor of Eating Disorders in the Department of Psychiatry, a Professor of Nutrition in the Gillings School of Global Public Health and the Founding Director of the Center of Excellence for Eating Disorders at the University of North Carolina at Chapel Hill.    Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  Eating Disorders Genetics Initiative (EDGI) 2 - edgi2.org  National Eating Disorders Association - nationaleatingdisorders.org  Families Empowered and Supporting the Treatment of Eating Disorders (FEAST) - feast-ed.org    🌟Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25  Register today at nei.global/spcongress25rc    Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 

Join Dr. Andy Cutler and Dr. Carla Sharp as they discuss the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also covers recent updates to the APA’s BPD guidelines.  Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean for Faculty and Research at the University of Houston. Additionally, she directs both the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center and the Developmental Psychopathology Lab at the university.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    🌟Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25  Register today at nei.global/spcongress25a    Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 

Dr. Roger S. McIntyre, a leading expert in treatment-resistant depression and bipolar disorder, joins Dr. Andrew Cutler to discuss the complexities of prescribing potentially unsafe drug combinations. They explore the intricacies of pharmacokinetics and pharmacodynamics, emphasizing the risks of polypharmacy. Key topics include the importance of monitoring drug interactions, the implications of anticholinergic medications, and the safety of stimulants in mood disorders. The conversation highlights guidelines for responsible prescribing and the challenges of managing treatment-resistant cases.

Join Dr. Andy Cutler as he speaks with Dr. Anita Clayton about one of the most common yet least discussed side effects of psychotropic medications—sexual dysfunction. They explore the different aspects of sexual dysfunction that may arise as a side effect, how to distinguish these from symptoms of psychiatric or medical disorders, and how to collaborate with patients to effectively address this challenging issue.  Anita H. Clayton, MD, Wilford W. Spradlin Professor and Chair of Psychiatry & Neurobehavioral Sciences, and Professor of Clinical Obstetrics & Gynecology at the University of Virginia School of Medicine, has focused her research on major depressive disorder, mood disorders associated with reproductive-life events in women (reproductive psychiatry), sexual dysfunction related to illness and medications, and the assessment and treatment of primary sexual disorders.    Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  Changes in Sexual Functioning Questionnaire short- form (CSFQ-14)  Validation study for CSFQ-14    🌟Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25  Register today at nei.global/spcongress25rc    Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter